Abstracts tagged "Biologic drugs"

Abstract Number: 2290 • 2017 ACR/ARHP Annual Meeting
Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data
Bin Huang¹, Esi Morgan², Chen Chen², Jinzhong Liu², Michelle Adams², Timothy Beukelman³, Hermine I. Brunner⁴ and Daniel J Lovell⁵, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati, OH
Background/Purpose: We compare the effectiveness of two approaches to treat Juvenile idiopathic arthritis (JIA): early combination of biologic and non-biologic disease modifying anti rheumatic drugs…
Abstract Number: 524 • 2017 ACR/ARHP Annual Meeting
Predictors of Mortality in RA Patients before Biologic Therapy
Debora Cordeiro Rosario¹, Camila Nobre Bulhoes¹, Rodrigo Peres Toledo¹, Karina Bonfiglioli², Ana C.M. Ribeiro³, Julio C. B. Moraes², Carla G.S. Saad², Clovis A Silva⁴, Eloisa Bonfa⁵ and Nadia E Aikawa², ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Several studies have evaluated mortality risk factors in rheumatoid arthritis (RA) but that are no data regarding baseline predictors of mortality in patients under…
Abstract Number: 2416 • 2017 ACR/ARHP Annual Meeting
Histopathological Change Caused By Biological Treatment in Rheumatoid Arthritis Synovial Tissue
Ayako Kubota, Toru Suguro, Masayuki Sekiguchi and Kazuaki Tsuchiya, Toho University Omori Medical Center, Tokyo, Japan
Background/Purpose: Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies…
Abstract Number: 605 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Exhibits a Favorable Safety Profile during 24 Weeks of Treatment in Subjects with Active Psoriatic Arthritis: Integrated Safety Analysis of Two Randomized, Placebo Controlled, Phase III Clinical Trials
Philip J Mease¹, Gerd R. Burmester², Susan Moriarty³, Olivier Benichou³, Wen Xu³ and Peter Nash⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. The objective of this analysis is to report the integrated safety of…
Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Regina Kurrasch⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Keio University School of Medicine, Tokyo, Japan, ³University of Toronto, Newmarket, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…
Abstract Number: 606 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Philip J Mease¹, Iain B. McInnes², Kristian Reich³, Peter Nash⁴, Mats Andersson⁵, Ken Abrams⁶, Luminita Pricop⁶ and Todd Fox⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, United Kingdom, ³Dermatologikum Hamburg, Hamburg, Germany, ⁴University of Queensland, Brisbane, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Pooled safety data from secukinumab psoriasis (PSO) and psoriatic arthritis (PsA) clinical trial programs after ~1 year of exposure have been reported previously.1, 2…
Abstract Number: 2454 • 2017 ACR/ARHP Annual Meeting
Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas^1,2, George W. Reed^2,3, Chitra Karki⁴, Jenny Griffith⁵, Martha Skup⁵, Vishvas Garg⁵ and Joel Kremer^2,6, ¹Columbia University, New York, NY, ²Corrona LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Corrona, LLC, Southborough, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Adalimumab (ADA) was approved in the US in 2002 for rheumatoid arthritis (RA), and subsequently approved for the management of other inflammatory diseases such…
Abstract Number: 624 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two Year Results from a Phase 3 Trial
Philip S. Helliwell¹, Eric Lespessailles², Catherine Shuler³, Lotus Mallbris³, Janelle Erickson³ and Roy Fleischmann⁴, ¹St. Luke's Hospital and University of Leeds, Bradford, United Kingdom, ²University Orleans, Orleans, France, ³Eli Lilly and Company, Indianapolis, IN, ⁴Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. In the SPIRIT-P1 phase 3 study (NCT01695239), IXE was superior to placebo…
Abstract Number: 2472 • 2017 ACR/ARHP Annual Meeting
Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Daniel Aletaha¹, Carter Thorne², Michael Schiff³, Masayoshi Harigai⁴, Prasheen Agarwal⁵, Ravi Rao⁶, Christopher Cohen⁷, Ben Cheng⁵, Kurt Brown⁷ and Benjamin Hsu⁵, ¹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²University of Toronto, Newmarket, ON, Canada, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ⁷GlaxoSmithKline, Collegeville, PA
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, is in development for rheumatoid arthritis (RA) in…
Abstract Number: 628 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
Bernard Combe¹, Peter Nash², David Adams³, Lisa Kerr³ and Olivier Benichou³, ¹Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ²University of Queensland, Brisbane, Australia, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. Here, we present integrated efficacy data at Week 24 from two phase 3…
Abstract Number: 2473 • 2017 ACR/ARHP Annual Meeting
Sirukumab Subcutaneous Dose Regimens Maintain Clinical Response over Dosing Intervals in Rheumatoid Arthritis Patients: Results from a Phase 3 Study
David M. Brooks¹, Michael Plotnick², Nicola J. Williams³, Regina Kurrasch¹, Yanli Zhuang², Debra J. Tompson³, Benjamin Hsu² and Ravi Rao³, ¹GlaxoSmithKline, Collegeville, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in rheumatoid arthritis (RA)…
Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Derek Haaland¹, Anna Jaroszynska², B Haraoui³, Suneil Kapur⁴, Jacqueline Stewart⁵, Wojciech Olsynzynski⁶, Keltie Anderson⁷, Raman Rai⁸, Michael Starr⁹, Alexander Tsoukas¹⁰, Eliofotisti Psaradellis¹¹, Emmanouil Rampakakis¹¹, Cathy Tkaczyk¹², Allen J Lehman¹³, Francois Nantel¹² and Brendan Osborne¹², ¹Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ²Private practice, Burlington, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵Penticton Regional Hospital, Penticton, BC, Canada, ⁶University of Saskatchewan, Saskatoon, ON, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Hamilton, ON, Canada, ⁹Rheumatology, McGill University, Pointe-Claire,, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…
Abstract Number: 2500 • 2017 ACR/ARHP Annual Meeting
Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register
Gary J. Macfarlane, Gareth T. Jones and Joanna Shim, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: Patients with axial spondyloarthritis (axSpA) identify the ability to stay at work as a priority. Biologic therapy improves disease activity and quality of life…
Abstract Number: 1045 • 2016 ACR/ARHP Annual Meeting
2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis
Désirée van der Heijde¹, Sofia Ramiro², Robert Landewé³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Alexandre Sepriano², Andrea Regel⁶, John D. Reveille⁷ and Jürgen Braun⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: In 2010 the latest ASAS-EULAR recommendations for AS and the ASAS recommendations for the use of TNF-inhibitors (TNFi) have been published. Since then new…
Abstract Number: 3219 • 2016 ACR/ARHP Annual Meeting
Altered microRNA Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals the Pathogenic Profile of These Cells. Effect of Biological Therapies
Nuria Barbarroja¹, Ivan Arias de la Rosa¹, Carlos Perez-Sanchez¹, Yolanda Jiménez-Gómez¹, Maria Carmen Abalos-Aguilera², Miguel Angel Caracuel-Ruiz³, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega-Castro¹, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras¹, Chary Lopez-Pedrera¹ and Patricia Ruiz-Limon², ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain
Background/Purpose: MicroRNAs (miRNA) have recently emerged as a new class of modulators of gene expression, regulating inflammation, degradation of extracellular matrix and invasive behavior of the…

« Previous Page
1
…
4
5
6
7
8
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].